Every 8-K that Corvus Pharmaceu (CRVS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CRVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRVS filings page.
Corvus Pharmaceuticals, Inc. reported that it issued a press release on August 6, 2026 covering its financial results for the three and six months ended June 30, 2026, its financial position as of June 30, 2026, and a broader business update.
The press release is furnished as Exhibit 99.1. Corvus states that the information related to these results and the exhibit is being furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934 and will only be incorporated into other securities law filings by specific reference.
Corvus Pharmaceuticals, Inc. reported that director Ian T. Clark delivered notice on July 21, 2026 of his intention to resign from the company’s board of directors, effective July 22, 2026. The company acknowledged and thanked Mr. Clark for his significant contributions during over nine years of board service.
Corvus Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders, where stockholders voted on director elections, auditor ratification, and executive compensation.
Two Class I directors, Richard A. Miller, M.D., and Linda S. Grais, M.D., J.D., were elected to serve until the 2029 annual meeting. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, on a non-binding advisory basis, stockholders approved the compensation of the company’s named executive officers. A total of 73,021,854 shares of common stock were voted out of 84,090,424 shares outstanding as of the April 16, 2026 record date.
Corvus Pharmaceuticals reported final results from a randomized, blinded, placebo-controlled Phase 1 trial of oral ITK inhibitor soquelitinib in 72 patients with moderate-to-severe atopic dermatitis who had failed at least one prior topical or systemic therapy. Thirty-five percent had previously received systemic treatment, yet the drug showed dose-dependent efficacy and additional benefit with longer dosing. In the 200 mg twice-daily cohorts, 50% (cohort 3) and 75% (cohort 4) of patients reached EASI 75, with higher response rates in the longer 56-day cohort and durable disease control through 30–90 days of drug-free follow up without rebound or need for rescue medication. Safety appeared favorable, with adverse events in 41.7% of both soquelitinib and placebo groups, all Grade 1–2, no serious events, and no significant lab abnormalities. Extensive biomarker work suggested soquelitinib modulates Th2/Th17 pathways, increases persistent Treg cells, and affects JAK-STAT signaling, aligning with its proposed mechanism. Corvus is now enrolling a roughly 200-patient Phase 2 SIERRA1 trial in atopic dermatitis, while partner Angel Pharmaceuticals runs a parallel Phase 1b/2 study in China.
Corvus Pharmaceuticals reported first quarter 2026 results and a major strengthening of its balance sheet while advancing its lead ITK inhibitor, soquelitinib. Cash, cash equivalents and marketable securities rose to $236.7 million as of March 31, 2026, including $189.4 million in net financing proceeds completed in January. Management believes this will fund operations into the second quarter of 2028.
R&D expenses increased to $11.2 million from $7.5 million a year earlier, mainly from higher soquelitinib clinical trial and personnel costs. The company posted a net loss of $13.7 million, versus net income of $15.2 million in 2025 that was driven by a large non-cash warrant liability revaluation.
Corvus initiated a Phase 2 atopic dermatitis trial for soquelitinib, continues a registrational Phase 3 trial in relapsed/refractory peripheral T cell lymphoma, and is preparing additional Phase 2 studies in hidradenitis suppurativa and asthma, highlighting a broader immune-disease strategy around ITK inhibition.
Corvus Pharmaceuticals appointed Andrew C. Chan, M.D., Ph.D. to its Board of Directors, effective April 23, 2026. He will serve as a Class II director with a term expiring at the 2027 annual stockholder meeting and will also join the Nominating and Corporate Governance Committee.
Under the company’s non-employee director compensation program, Dr. Chan will receive a $35,000 annual cash retainer for Board service and an initial stock option for 30,000 shares of common stock under the 2016 Equity Incentive Award Plan, plus $4,000 annually for Nominating Committee service. On the same date, longtime director Scott Morrison notified the company of his resignation from the Board, effective April 23, 2026.
Corvus Pharmaceuticals, Inc. established an amended at-the-market equity program to sell up to $200,000,000 of common stock through Jefferies LLC as sales agent under a newly filed automatic shelf registration on Form S-3.
The new Amended and Restated Open Market Sale Agreement replaces a prior $100,000,000 arrangement under which no shares had been sold as of March 13, 2026. Jefferies will use commercially reasonable efforts to place shares by various permitted methods and may earn a commission of up to 3.0% of the gross sales price per share.
Corvus Pharmaceuticals provided a business update and reported fourth quarter and full year 2025 results, emphasizing progress for its lead ITK inhibitor soquelitinib and a strengthened balance sheet.
In atopic dermatitis, cohort 4 of the Phase 1 trial showed encouraging efficacy, with 75% of soquelitinib patients achieving EASI 75, 25% achieving EASI 90 and 33% reaching IGA 0/1, compared with 20%, 0% and 0% for placebo, alongside a clean safety profile and no dose modifications or treatment-related discontinuations across more than 14,000 treatment days. Corvus has initiated a Phase 2 atopic dermatitis trial and continues enrolling a registrational Phase 3 trial in relapsed/refractory peripheral T cell lymphoma, where soquelitinib holds Orphan Drug and Fast Track designations.
As of December 31, 2025, Corvus held $56.8 million in cash, cash equivalents and marketable securities, not including approximately $189.4 million in net proceeds from a January 23, 2026 public offering, which it expects will fund operations into the second quarter of 2028. Research and development expenses rose to $33.7 million in 2025 from $19.4 million in 2024 as clinical programs expanded, and net loss narrowed to $15.3 million from $62.3 million, partly reflecting prior-period warrant liability fair value changes.
Corvus Pharmaceuticals entered an underwriting agreement for an underwritten public stock offering of 7,900,677 shares of common stock at a public offering price of $22.15 per share. Underwriters agreed to buy the shares at $20.821 per share and were granted a 30‑day option to purchase an additional 1,185,101 shares, which they exercised in full on January 22, 2026. After underwriting discounts, commissions and estimated expenses and including the option shares, Corvus expects net proceeds of approximately $188.3 million. The company plans to use these funds for working capital and general corporate purposes, including capital expenditures, research and development for its Phase 3 T cell lymphoma and multiple Phase 2 dermatology and asthma trials, as well as sales, marketing and administrative expenses.
Corvus Pharmaceuticals, Inc. filed an update explaining that on January 20, 2026 it suspended sales under its Open Market Sale AgreementSM with Jefferies LLC. This at-the-market program had been established under a Form S-3 shelf registration and related August 6, 2024 prospectus supplement to permit sales of up to $100 million of ATM Shares of common stock. Before the suspension, no ATM Shares had been sold, so the full $100 million of ATM Shares remained available. The agreement with Jefferies remains in effect, but the company states it will not sell common stock under this program unless and until it files a new prospectus supplement or registration statement with the SEC.
Corvus Pharmaceuticals reported positive new data from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis. Patients receiving 200 mg twice daily for 56 days showed a mean 70% reduction in EASI scores, compared with 40% for placebo, and 75% achieved EASI 75 versus 20% on placebo. Responses deepened between days 28 and 56, with statistically significant separation at day 56 and activity seen even in patients previously treated with systemic therapies such as dupilumab and JAK inhibitors. Biomarker results support the drug’s ITK inhibition mechanism, indicating immune rebalancing across multiple T cell pathways. Safety in cohort 4 remained favorable, with only Grade 1–2 adverse events and no serious events. Based on these results, the company plans to start a Phase 2 trial in the first quarter of 2026.
Corvus Pharmaceuticals (CRVS) filed an 8-K to furnish a press release covering its financial results for the three and nine months ended September 30, 2025, along with a business update. The press release is provided as Exhibit 99.1.
The company states the information under Item 2.02 and Exhibit 99.1 is furnished and not filed under the Exchange Act. Corvus’s common stock trades on the Nasdaq Global Market under the symbol CRVS.
Corvus Pharmaceuticals, Inc. appointed David Moore to its Board of Directors effective October 2, 2025. He will serve as a Class III director with a term extending to the 2028 annual meeting of stockholders and will also join the Compensation Committee and the Nominating and Corporate Governance Committee.
Under the company’s non-employee director compensation program, Mr. Moore will receive a $35,000 annual cash retainer for Board service, plus $6,000 annually for serving on the Compensation Committee and $4,000 annually for serving on the Nominating Committee, each earned quarterly and prorated for the current quarter. He will also receive an initial stock option to purchase 30,000 shares of common stock under the 2016 Equity Incentive Award Plan and will be eligible for future equity awards according to the same program. Mr. Moore will enter into the company’s standard indemnification agreement for directors and executive officers.